Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs ARI 3037MO (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Arisaph Pharmaceuticals
- 05 Aug 2016 Status changed from recruiting to completed.
- 21 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
- 21 Aug 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.